Cargando…

COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future

Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include comorbidities, uncontrolled disease, and current line of treatment. Although COVID-19 vaccines have afforded some leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Victoria G, Teh, Benjamin W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401617/
https://www.ncbi.nlm.nih.gov/pubmed/37539765
http://dx.doi.org/10.1093/infdis/jiad174
_version_ 1785084704844677120
author Hall, Victoria G
Teh, Benjamin W
author_facet Hall, Victoria G
Teh, Benjamin W
author_sort Hall, Victoria G
collection PubMed
description Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include comorbidities, uncontrolled disease, and current line of treatment. Although COVID-19 vaccines have afforded some level of protection against infection and severe disease among patients with solid tumors and hematologic malignancies, decreased immunogenicity and real-world effectiveness have been observed among this population compared with healthy individuals. Characterizing and understanding the immune response to increasing doses or differing schedules of COVID-19 vaccines among patients with cancer is important to inform clinical and public health practices. In this article, we review SARS-CoV-2 susceptibility and immune responses to COVID-19 vaccination in patients with solid tumors, hematologic malignancies, and those receiving hematopoietic stem cell transplant or chimeric-antigen receptor T-cell therapy.
format Online
Article
Text
id pubmed-10401617
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104016172023-08-05 COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future Hall, Victoria G Teh, Benjamin W J Infect Dis COVID-19 Vaccination Supplement Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include comorbidities, uncontrolled disease, and current line of treatment. Although COVID-19 vaccines have afforded some level of protection against infection and severe disease among patients with solid tumors and hematologic malignancies, decreased immunogenicity and real-world effectiveness have been observed among this population compared with healthy individuals. Characterizing and understanding the immune response to increasing doses or differing schedules of COVID-19 vaccines among patients with cancer is important to inform clinical and public health practices. In this article, we review SARS-CoV-2 susceptibility and immune responses to COVID-19 vaccination in patients with solid tumors, hematologic malignancies, and those receiving hematopoietic stem cell transplant or chimeric-antigen receptor T-cell therapy. Oxford University Press 2023-08-04 /pmc/articles/PMC10401617/ /pubmed/37539765 http://dx.doi.org/10.1093/infdis/jiad174 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle COVID-19 Vaccination Supplement
Hall, Victoria G
Teh, Benjamin W
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
title COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
title_full COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
title_fullStr COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
title_full_unstemmed COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
title_short COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
title_sort covid-19 vaccination in patients with cancer and patients receiving hsct or car-t therapy: immune response, real-world effectiveness, and implications for the future
topic COVID-19 Vaccination Supplement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401617/
https://www.ncbi.nlm.nih.gov/pubmed/37539765
http://dx.doi.org/10.1093/infdis/jiad174
work_keys_str_mv AT hallvictoriag covid19vaccinationinpatientswithcancerandpatientsreceivinghsctorcarttherapyimmuneresponserealworldeffectivenessandimplicationsforthefuture
AT tehbenjaminw covid19vaccinationinpatientswithcancerandpatientsreceivinghsctorcarttherapyimmuneresponserealworldeffectivenessandimplicationsforthefuture